Education
About Us
Working with TipRanks
Follow Us
4D Molecular Therapeutics (FDMT)
NASDAQ:FDMT
Total Valuation
4D Molecular Therapeutics has a market cap or net worth of $161.67M. The enterprise value is ―.
Market Cap$161.67M
Enterprise Value―
Share Statistics
4D Molecular Therapeutics has 46,324,642 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding46,324,642
Owned by Insiders12.57%
Owned by Institutions34.38%
Financial Efficiency
4D Molecular Therapeutics’s return on equity (ROE) is -0.32 and return on invested capital (ROIC) is -34.99%.
Return on Equity (ROE)-0.32
Return on Assets (ROA)-0.29
Return on Invested Capital (ROIC)-34.99%
Return on Capital Employed (ROCE)-0.35
Revenue Per Employee163.00
Profits Per Employee-708.67K
Employee Count227
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of 4D Molecular Therapeutics is -1.87. 4D Molecular Therapeutics’s PEG ratio is 0.51.
PE Ratio-1.87
PS Ratio0.00
PB Ratio0.38
Price to Fair Value0.59
Price to FCF-1.24
Price to Operating Cash Flow-1.45
PEG Ratio0.51
Income Statement
In the last 12 months, 4D Molecular Therapeutics had revenue of 37.00K and earned -160.87M in profits. Earnings per share was -2.98.
Revenue37.00K
Gross Profit37.00K
Operating Income-187.84M
Pretax Income-160.87M
Net Income-160.87M
EBITDA-187.84M
Earnings Per Share (EPS)-2.98
Cash Flow
In the last 12 months, operating cash flow was -134.59M and capital expenditures -949.00K, giving a free cash flow of -135.53M billion.
Operating Cash Flow-134.59M
Free Cash Flow-135.53M
Free Cash Flow per Share-2.93
Dividends & Yields
4D Molecular Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.40
52-Week Price Change-85.73%
50-Day Moving Average3.32
200-Day Moving Average7.23
Relative Strength Index (RSI)50.36
Average Volume (3m)505.94K
Important Dates
4D Molecular Therapeutics upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
4D Molecular Therapeutics as a current ratio of 14.92, with Debt / Equity ratio of 4.82%
Current Ratio14.92
Quick Ratio14.92
Debt to Market Cap0.08
Net Debt to EBITDA0.66
Interest Coverage Ratio0.00
Taxes
In the past 12 months, 4D Molecular Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
4D Molecular Therapeutics EV to EBITDA ratio is -0.94, with an EV/FCF ratio of -1.31.
EV to Sales4.75K
EV to EBITDA-0.94
EV to Free Cash Flow-1.31
EV to Operating Cash Flow-1.31
Balance Sheet
4D Molecular Therapeutics has $424.88M in cash and marketable securities with $24.61M in debt, giving a net cash position of -$400.27M billion.
Cash & Marketable Securities$424.88M
Total Debt$24.61M
Net Cash-$400.27M
Net Cash Per Share-$8.64
Tangible Book Value Per Share$9.47
Margins
Gross margin is 100.00%, with operating margin of -507678.38%, and net profit margin of -434778.38%.
Gross Margin100.00%
Operating Margin-507678.38%
Pretax Margin-434778.38%
Net Profit Margin-434778.38%
EBITDA Margin-507678.38%
EBIT Margin-507678.38%
Analyst Forecast
The average price target for 4D Molecular Therapeutics is $30.83, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$30.83
Price Target Upside801.46% Upside
Analyst ConsensusModerate Buy
Analyst Count7
Revenue Growth Forecast―
EPS Growth Forecast―